180 Wealth Advisors LLC Boosts Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

180 Wealth Advisors LLC boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.4% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 4,672 shares of the medical research company’s stock after purchasing an additional 320 shares during the quarter. 180 Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,325,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of TMO. Ellevest Inc. grew its stake in shares of Thermo Fisher Scientific by 137.5% during the 2nd quarter. Ellevest Inc. now owns 95 shares of the medical research company’s stock worth $28,000 after purchasing an additional 55 shares during the period. American National Bank acquired a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $29,000. Massey Quick Simon & CO. LLC acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $30,000. Candriam Luxembourg S.C.A. grew its stake in shares of Thermo Fisher Scientific by 11.3% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 104,069 shares of the medical research company’s stock worth $30,000 after purchasing an additional 10,569 shares during the period. Finally, Redhawk Wealth Advisors Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $31,000. 88.21% of the stock is owned by institutional investors.

In other news, CEO Marc N. Casper sold 2,271 shares of Thermo Fisher Scientific stock in a transaction on Friday, September 13th. The stock was sold at an average price of $298.00, for a total transaction of $676,758.00. Following the transaction, the chief executive officer now owns 283,502 shares in the company, valued at approximately $84,483,596. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $284.83, for a total value of $14,241,500.00. Following the transaction, the chief executive officer now owns 342,193 shares in the company, valued at approximately $97,466,832.19. The disclosure for this sale can be found here. In the last quarter, insiders have sold 54,104 shares of company stock worth $15,418,539. Insiders own 0.45% of the company’s stock.

Shares of TMO stock opened at $280.99 on Wednesday. The stock’s fifty day moving average is $288.36 and its two-hundred day moving average is $281.45. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.07 and a current ratio of 1.49. The firm has a market capitalization of $112.70 billion, a P/E ratio of 25.27, a PEG ratio of 1.84 and a beta of 1.13. Thermo Fisher Scientific Inc. has a fifty-two week low of $208.34 and a fifty-two week high of $305.45.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.04 EPS for the quarter, topping the consensus estimate of $3.01 by $0.03. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The business had revenue of $6.32 billion for the quarter, compared to analyst estimates of $6.31 billion. During the same quarter in the previous year, the firm earned $2.75 EPS. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 12.25 earnings per share for the current year.

TMO has been the topic of a number of analyst reports. Credit Suisse Group reaffirmed a “buy” rating and set a $310.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. Barclays set a $330.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Monday, July 15th. Needham & Company LLC raised their price objective on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Finally, ValuEngine cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $305.27.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: Systematic Risk

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.